According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...

Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

Some companies have announced diversity rollbacks — but many more are deleting or softening language from their investor ...

Here’s a highlight of Auburn-Opelika honorees who made the community proud with their achievements in January.

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...